Skip to content
Research Article Open access CC BY 4.0

Assessment of the Cost Differences and Variability of Medicines for the Treatment of Heart Failure in India

Chakrapani Kumar, Rajesh Kumar, Akhilesh Kumar Rana, Sunil Kumar Singh, Shruti Singh

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 38–49 · Published 15 Sep 2023

10.9734/jamps/2023/v25i8635

Abstract

Introduction: Heart failure, a global health concern affecting millions, has varying prevalence, classifications, and treatments. Standard therapy includes ACE inhibitors, beta blockers, and diuretics. Newer options like ARNIs and sinoatrial node modulators are recommended. There is no previous research on cost disparity in heart failure medication in India. The objective of this research, which aims at reducing treatment costs, increasing adherence to therapy and using medicines more carefully, is to assess the differences in cost between various medicinal products. Methods: The maximum and minimum price of each brand of the drugs given in Indian rupees (INR) was noted by using ‘Drug Today’ (January to April 2023, volume II). The cost range, cost ratio, and the percentage cost variation for individual drug brands were calculated. The cost of tablets/capsule was calculated and the cost ratio and percentage cost variation of various brands was compared. Results: After calculation of cost ratio and percentage cost variation for each brands of drug used in the management of Heart failure, tab Propranolol (40 mg) had a maximum percentage cost variation of 678% and a cost ratio of 7.78 while tab Candesartan (8 mg) had a minimum percentage cost variation of 006% and cost ratio of 1.06. Ideally we use the drug which cost ratio less than 2 and percentage cost variation less than 100. Conclusions: There is a wide variation in the price of different brands of drug used in the management of Heart failure available in India. The clinicians prescribing these drugs should be aware of these variations to reduce the financial burden of drug therapy and improve compliance.

Heart failure cost ratio percentage cost variation

References (15)

  1. 1 The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure [DOI]
  2. 2 Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure [DOI]
  3. 3 Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure [DOI]
  4. 4 Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) [DOI]
  5. 5 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial [DOI]
  6. 6 Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) [DOI]
  7. 7 The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure [DOI]
  8. 8 Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure [DOI]
  9. 9 Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial [DOI]
  10. 10 Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials [DOI]
  11. 11 Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure [DOI]
  12. 12 The epidemiological features of heart failure in developing countries: a review of the literature [DOI]
  13. 13 Heart failure: epidemiology and prevention in India.
  14. 14 Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure [DOI]
  15. 15 Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

23

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.